A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells

The outlook for patients with refractory/relapsed acute myeloid leukemia (AML) remains poor, with conventional chemotherapeutic treatments often associated with unacceptable toxicities, including severe infections due to profound myelosuppression. Thus there exists an urgent need for more effective...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Autores principales: Kovtun, Yelena, Jones, Gregory E., Adams, Sharlene, Harvey, Lauren, Audette, Charlene A., Wilhelm, Alan, Bai, Chen, Rui, Lingyun, Laleau, Rassol, Liu, Fenghua, Ab, Olga, Setiady, Yulius, Yoder, Nicholas C., Goldmacher, Victor S., Chari, Ravi V. J., Pinkas, Jan, Chittenden, Thomas
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2018
Materias:
Myeloid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5916008/
https://ncbi.nlm.nih.gov/pubmed/29661755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018017517
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares